Compounds > alpha-2'-deoxythioguanosine
Page last updated: 2024-12-10

alpha-2'-deoxythioguanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-2'-deoxythioguanosine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3005835
CHEMBL ID3230221
SCHEMBL ID9222786
MeSH IDM0042528

Synonyms (18)

Synonym
2-amino-9-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purine-6-thione
2133-81-5
alpha-tgdr
2-amino-9-(2-deoxy-alpha-d-erythro-pentofuranosyl)-9h-purine-6-thiol
alpha-2'-deoxy-6-thioguanosine
alpha-thiodeoxyguanosine
alpha-deoxythioguanosine
thioguanine 9alphad-2'-deoxyriboside
9h-purine-6(1h)-thione, 2-amino-9-(2-deoxy-alpha-d-erythro-pentofuranosyl)-
alpha-2'-deoxythioguanosine
6h-purine-6-thione, 2-amino-9-(2-deoxy-alpha-d-erythro-pentofuranosyl)-1,9-dihydro-
t-dguo
CCG-35478
CHEMBL3230221
SCHEMBL9222786
2-amino-9-(2-deoxy-alpha-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purine-6-thione
2-amino-9-((2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3h-purine-6(9h)-thione
DTXSID901139308
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1133841Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of tritiated thymidine incorporation into nucleic acids1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1124751Stability in RPMI 1640 assessed as formation of thioguanine after 24 hrs in presence of 10% dialyzed horse serum1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124754Stability in human WIL2 cells assessed as formation of thioguanine1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1133835Antitumor activity in mouse L1210 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 5 of challenge relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1124755Antiproliferative activity against human WIL2 cells assessed as decrease in cell number at 100 to 300 uM measured every 24 hrs by electronic particle counting analysis in presence of 10% dialyzed horse serum1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1133840Antitumor activity in mouse P388 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 9 of challenge relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1124752Stability in RPMI 1640 after 24 hrs in presence of 10% fetal calf serum1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124740Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 200 uM measured immediately post compound treatment by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 1 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124744Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 300 uM measured at 23.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 3.4 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1133837Antitumor activity in mouse L1210 cells allografted in mouse assessed as increase in survival time at optimal dose administered qd on days 1 to 16 of challenge relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1124741Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 300 uM measured immediately post compound treatment by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 1 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1133842Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of tritiated uridine incorporation into nucleic acids1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential antitumor agents. Some sulfur-substituted derivatives of alpha- and beta-2'-deoxythioguanosine.
AID1124733Acid-insoluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as detection of [35S] in nucleoside at 2.6 umol after 4 hrs by scintillation counting analysis1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124732Acid-insoluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed per mg of DNA at 2.6 umol, ip after 4 hrs by scintillation counting analysis1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124743Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 200 uM measured at 23.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 3.4 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124735Acid-soluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as detection of [35S] in nucleoside per mg of DNA at 2.6 umol after 4 hrs by scintillation counting analysis1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124753Stability in RPMI 1640 after 20 mins in presence of 10% fetal calf serum1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124738Acid-soluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as snake venome 5'-nucleotidase-mediated nucleotide hydrolysis at 2.6 umol after 2 hrs1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124746Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 200 uM measured at 47.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 10.7 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124739Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 100 uM measured immediately post compound treatment by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 1 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124745Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 100 uM measured at 47.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 10.7 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124742Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 100 uM measured at 23.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 3.4 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124747Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 300 uM measured at 47.5 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 10.7 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124737Acid-soluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as wheat germ 3'-nucleotidase-mediated nucleotide hydrolysis at 2.6 umol after 1 hr1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124749Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 200 uM measured at 71 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 16 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124736Acid-soluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as detection of [35S] in nucleotide per mg of DNA at 2.6 umol after 4 hrs by scintillation counting analysis1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124748Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 100 uM measured at 71 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 16 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124734Acid-insoluble DNA incorporation in mouse Mecca lymphosarcoma ascite tumor allografted in AKD2F1 mouse assessed as detection of [35S] in nucleotide at 2.6 umol after 4 hrs by scintillation counting analysis1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
AID1124750Antiproliferative activity against human WIL2 cells assessed as cell number per ml at 300 uM measured at 71 hrs by electronic particle counting analysis in presence of 10% fetal calf serum (Rvb = 16 x 10'-5/ml)1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.00)18.7374
1990's2 (10.00)18.2507
2000's2 (10.00)29.6817
2010's7 (35.00)24.3611
2020's6 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		2.4110antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		2.0210diazine;
pyrimidines		Daphnia magna metabolite
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.4110beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		2.4110nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
vidarabine phosphate
Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.		2.4110
etoposide
[no description available]		2.4110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
deoxyuridine triphosphate
[no description available]		2.110deoxyuridine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		2.4110organoiodine compound
fludarabine
[no description available]		2.4110purine nucleoside
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		2.4520aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		2.45202-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
beta-2'-deoxythioguanosine
beta-2'-deoxythioguanosine: RN given refers to parent cpd		2.3920
thiouridine
Thiouridine: A photoactivable URIDINE analog that is used as an affinity label.. 4-thiouridine : A thiouridine in which the oxygen replaced by sulfur is that at C-4.		2.0210nucleoside analogue;
thiouridine		affinity label;
antimetabolite
4-thio-2'-deoxyuridine
4-thio-2'-deoxyuridine: RN in Chemline for 2-thio-isomer: 2i35059-12-2		2.0210
phosphoramidite
phosphoramidite: structure in first source. phosphoramidite : A compound with the general formula (RO)2PNR2. Phosphoramidites can be regarded as phosphites that have an NR2 instead of an OH group, or as amides of phosphorous acid.		2.0210
ceritinib
ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.		2.4110aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
imetelstat
[no description available]		2.4110
deoxyguanosine
[no description available]		4.27170purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyguanosine triphosphate
[no description available]		2.110deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.110guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanine
[no description available]		2.4202-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		2.0210guanosines;
purines D-ribonucleoside		fundamental metabolite
8-bromoguanosine
[no description available]		2.0210purine nucleoside
ConditionIndicatedRelationship StrengthStudiesTrials
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		01.9510
Experimental Neoplasms
[description not available]		02.420
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		01.9510
Leukemia L 1210
[description not available]		01.9510
Experimental Leukemia
[description not available]		01.9510
Leukemia, Lymphocytic
[description not available]		01.9510
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9510
Benign Neoplasms, Brain
[description not available]		02.6320
Glial Cell Tumors
[description not available]		02.6320
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.6320
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.6320
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.4110
Lung Adenocarcinoma
[description not available]		02.2510
Cancer of Lung
[description not available]		02.6120
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.2510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.6120
Benign Neoplasms
[description not available]		02.420
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.420
Asthma, Bronchial
[description not available]		02.3110
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.3110
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		02.3110
Malignant Melanoma
[description not available]		02.1710
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1710
Brain Stem Neoplasms, Primary
[description not available]		02.1710
Arachnoidal Cerebellar Sarcoma, Circumscribed
[description not available]		02.1710
Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)		02.1710
Brain Stem Neoplasms
Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.		02.1710
Carcinoma, Non-Small Cell Lung
[description not available]		02.1710
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.1710
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.1110
Bowel Diseases, Inflammatory
[description not available]		02.1310
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.1310